Hospital
Madison Co Memorial Hospital
Madison Co Memorial Hospital was paid $722K by Medicaid between Jan 2018 and Sep 2024, across 85 billing codes. Its largest line is 41899, Unlisted procedure, dentoalveolar structures — 22% of everything it billed.
33Billing provider infoMADISON CO MEMORIAL HOSPITAL
REXBURG, ID 83440
REXBURG, ID 83440
33aNPI1992747570assigned 06/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$722K
24GClaims55,327
24DCodes billed85
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other General Acute Care Hospital providers in Idaho
Rank by total paid#10 of 12
Median peer was paid$3.12M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,520 | $225K | |
| 2019 | 19,755 | $250K | |
| 2020 | 12,679 | $235K | |
| 2021 | 1,176 | $6K | |
| 2022 | 1,530 | $5K | |
| 2023 | 1,150 | $1K | |
| 2024incomplete | 517 | $369.06 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 41899 | Unlisted procedure, dentoalveolar structures | 22% | 494 | 489 | $156K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 10% | 185 | 184 | $74K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.6% | 479 | 466 | $62K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 6.1% | 1,036 | 931 | $44K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 5.7% | 13 | 13 | $41K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.7% | 525 | 450 | $34K |
| 80053 | Comprehensive metabolic panel | 4.6% | 5,394 | 4,581 | $33K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.4% | 1,267 | 325 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.9% | 6,108 | 4,773 | $28K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.9% | 660 | 193 | $21K |
| 36415 | Collection of venous blood by venipuncture | 2.4% | 7,736 | 6,061 | $17K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 348 | 334 | $14K |
73 more codes
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.9% | 12 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.8% | 1,136 | $13K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 24 | $12K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 690 | $9K |
| 99283 | Emergency room visit (moderate) | 1.1% | 177 | $8K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.0% | 392 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.0% | 97 | $7K |
| 81001 | <1% | 2,661 | $7K | |
| 81025 | <1% | 737 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 83 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 116 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 598 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,561 | $4K |
| 85027 | <1% | 977 | $4K | |
| 84484 | <1% | 583 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,308 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 73 | $3K |
| 83690 | <1% | 544 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 526 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 52 | $3K |
| 82247 | <1% | 448 | $2K | |
| 74018 | <1% | 191 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,122 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 406 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 87 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,917 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 468 | $2K |
| 84439 | <1% | 249 | $2K | |
| 80061 | Lipid panel | <1% | 275 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 69 | $1K |
| 84702 | <1% | 107 | $1K | |
| 80306 | <1% | 114 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,806 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,002 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,209 | $1K |
| 85378 | <1% | 166 | $989.51 | |
| 83735 | <1% | 268 | $935.33 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 420 | $900.08 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 599 | $805.53 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 37 | $784.76 |
| 99285 | Emergency room visit (most serious) | <1% | 16 | $747.45 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 186 | $744.93 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 193 | $720.67 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 32 | $655.34 |
| 97161 | <1% | 12 | $652.75 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 894 | $636.32 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,456 | $610.61 |
| 73630 | <1% | 42 | $559.89 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14 | $411.92 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 28 | $372.84 |
| 86140 | <1% | 91 | $370.34 | |
| 86756 | <1% | 26 | $365.90 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19 | $322.34 |
| 85610 | <1% | 103 | $318.08 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 54 | $281.92 |
| 85651 | <1% | 108 | $267.06 | |
| 73130 | <1% | 14 | $255.04 | |
| 73610 | <1% | 13 | $196.13 | |
| 82248 | <1% | 45 | $186.82 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 59 | $173.70 |
| 82728 | <1% | 14 | $106.03 | |
| 86900 | <1% | 27 | $89.87 | |
| 87070 | <1% | 13 | $89.48 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 839 | $79.43 |
| 87040 | <1% | 17 | $73.29 | |
| 86901 | <1% | 14 | $58.47 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 29 | $14.15 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 136 | $6.15 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $5.30 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 42 | $5.18 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 27 | $2.94 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 26 | $1.24 |
| A9270 | Non-covered item or service | 0% | 174 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGONZALES, RACHEL (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Madison Co Memorial Hospital | Rexburg, ID | $2.64M |
| Madison Co Memorial Hospital | Rexburg, ID | $1.56M |
| Madison Memorial Hospital | Rexburg, ID | $1.17M |
| Madison Co Memorial Hospital | Rexburg, ID | $4K |
| Madison Co Memorial Hospital | Rigby, ID | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.